Navigation Links
Soligenix Reports Third Quarter 2011 Financial Results
Date:11/14/2011

e recommendation of an independent Data Safety Monitoring Board.  While we continue to analyze the dataset from this trial, we remain committed to evaluating all strategic options to re-establish the value of Soligenix, including through the development of our oral BDP programs for pediatric Crohn's disease, acute radiation syndrome and acute radiation enteritis as well as through our vaccines/biodefense programs with our novel thermostability technology and ricin toxin vaccine. We look forward to making news in some of these areas in the not too distant future."

Soligenix's Third Quarter and Recent News:

  • On October 11, 2011, Soligenix announced the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance related to the development of SGX203 (oral beclomethasone dipropionate, or oral BDP) for the treatment of pediatric Crohn's disease.
  • On September 15, 2011, Soligenix announced the recommendation of an independent Data Safety Monitoring Board to stop its confirmatory Phase 3 clinical trial for orBec® in the treatment of acute GI GVHD for futility.
  • On July 28, 2011, Soligenix announced the expansion and amendment of its North American licensing partnership with Sigma-Tau for the development and commercialization of orBec® (oral beclomethasone dipropionate or Oral BDP) into the European territory. As part of the amended agreement, Sigma-Tau made a $5 million payment to Soligenix. 

About Soligenix, Inc.

Soligenix is a development stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid that has been initially developed for the treatment of acute
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Soligenix Announces Formation of Pediatric Crohns Disease Medical Advisory Board
2. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
3. Soligenix Reports Second Quarter 2011 Financial Results and Reviews Accomplishments
4. Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe
5. Soligenix Announces Appointment of Jerome Zeldis, MD, PhD and Keith Brownlie, CPA to its Board of Directors
6. Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
7. Soligenix to Present at 13th Annual BIO CEO & Investor Conference
8. Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer
9. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
10. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
11. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Allakos Inc. ... $10 million investment from current investors to fund ... financing was completed following achievement of a key, ... program, and represents an extension of the company,s ... December 2012. With this additional financing, Allakos has ...
(Date:9/29/2014)... SAN DIEGO , 29 septembre 2014 ... Daiichi Sankyo) (TSE : 4568) et Ambit Biosciences (NASDAQ : ... accord de fusion définitif en vertu duquel Daiichi ... ordinaires en circulation d,Ambit Biosciences à 15 dollars ... offre publique d,achat qui sera suivie d,une fusion ...
(Date:9/29/2014)... -- BioMed Realty Trust, Inc. (NYSE: BMR ) ... approximately 200,000 square feet for 12 years with Baxter ... 650 East Kendall Street in Cambridge, Massachusetts ... a joint venture with Prudential Real Estate Investors. Baxter ... and development (R&D) center at the site for its ...
Breaking Medicine Technology:Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 2Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 3Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 4Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9BioMed Realty Trust Signs A New 12-Year Lease Establishing New Innovation And R&D Center In Kendall Square In Cambridge, Massachusetts 2BioMed Realty Trust Signs A New 12-Year Lease Establishing New Innovation And R&D Center In Kendall Square In Cambridge, Massachusetts 3
... Aging Now has been selected by the editors ... fastest-growing private companies. Stop Aging Now , a ... vitamins and supplements. (Logo:   http://photos.prnewswire.com/prnh/20100817/INC5000LOGO ) ... Stop Aging Now was placed in the top ...
... Orthocare Innovations has been honored with the 2010 da ... most innovative technologies for people with disabilities. Orthocare received ... Compas™ is a first-of-its-kind device that lets people with ... to improve the alignment of their prosthesis. The system ...
Cached Medicine Technology:Stop Aging Now Named to Prestigious Inc. 5000 List 2Orthocare Innovations Wins da Vinci Award for Compas™ Computerized Prosthesis Alignment System 2Orthocare Innovations Wins da Vinci Award for Compas™ Computerized Prosthesis Alignment System 3
(Date:9/30/2014)... By Kathleen Doheny ... (HealthDay News) -- Children who are given broad-spectrum antibiotics ... higher risk of becoming obese during childhood, new research ... organisms than narrow-spectrum ones, according to the study. ... need antibiotics, and which antibiotic you are picking," said ...
(Date:9/30/2014)... VA (PRWEB) September 30, 2014 Visit ... of Chestnut Hill and you will find a loving ... together, Amyotrophic Lateral Sclerosis. , Steve was ... or Lou Gehrig’s Disease – just before the couple’s ... primary caregiver. , A new video, “Care, Support ...
(Date:9/30/2014)... September 30, 2014 TrailMyx.com —the ... October Flavor of the Month: raw pumpkin seeds. , ... of squash”)—are rich in protein, and valued by experts ... multiple types of vitamin E. They are prized for ... and proper bowel function. , Of course, pumpkin seeds ...
(Date:9/30/2014)... 30, 2014 Thanks to ... National Children’s Oral Health Foundation: America’s ToothFairy® ... to non-profit clinical partners. These organizations are ... deliver comprehensive educational, preventive and treatment services ...     Just Kids Dental: $25,000 ...
(Date:9/30/2014)... 30, 2014 (HealthDay News) -- In books and movies, plots ... Now, new research suggests that the stereotype may ... looked at data on more than 12,000 people from Finland. ... in Turku, Finland, found that women typically preferred men who ... consistent throughout their lives. On the other hand, men ...
Breaking Medicine News(10 mins):Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 3Health News:Hospice Provides Care and Support to Patients and Family Caregivers with ALS 2Health News:TrailMyx.com Features October Flavor of the Month 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3Health News:When It Comes to Sex Partners, Men Prefer Younger Women: Study 2
... ALEXANDRIA, Va., Aug. 8 /PRNewswire-USNewswire/ National Hospice and,Palliative ... of the 2008 Circle of Life Award(R). This ... programs that,demonstrate superior vision, depth, and scope., ... American Hospital,Association,s annual summit in San Diego. This ...
... levels of testosterone may be a key factor in ... could help explain why males in a population are ... Previous research has linked testosterone, the male sex hormone, ... compared to females, experience more bouts of disease, and ...
... Children,s Hospital & Research Center Oakland continues to lead ... a new medical journal focused on children and teenagers. ... Pediatric Rehabilitation Department, is the founder and editor-in-chief of ... Approach . The quarterly journal released its second issue ...
... Eastern Insurance,Holdings, Inc. (Nasdaq: EIHI ... has executed a definitive agreement to acquire ... a transaction valued at,approximately $14.9 million, including ... wholly owned subsidiary is Employers Security Insurance,Company, ...
... of victims get to hospital quickly enough to limit damage, ... people who have strokes don,t act quickly enough to get ... study finds. , "One of the problems is that a ... stroke," said Kathryn M. Rose, a research associate professor of ...
... Aug. 7 Vapotherm, the,global leader in High ... the Food and Drug Administration (FDA) for Precision,Flow(TM), ... gas,blending, flow control and humidification technology into one ... gases., Other Vapotherm products are currently used ...
Cached Medicine News:Health News:Circle of Life Awards Recognize Innovative End-of-Life Care Providers 2Health News:Circle of Life Awards Recognize Innovative End-of-Life Care Providers 3Health News:Testosterone key to disease transmission 2Health News:Children's Hospital Oakland publishes first of its kind pediatric rehabilitation journal 2Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 2Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 3Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 4Health News:Many Miss Out on Stroke Treatment 2Health News:Many Miss Out on Stroke Treatment 3Health News:Vapotherm(R) Precision Flow(TM) Receives FDA 510(k) Clearance 2
... Model V-1000 is a new addition to the ... This high performance pump can achieve an ultimate ... of 64 L/min. Applications For ... concentrators Distillation applications from lab size ...
... deliver critical performance for all vacuum requirements. ... pump performance to suit all applications. The ... checking of proper oil levels at a ... designed to work with all Thermo Savant ...
... The OFP400 Oil-free Vacuum Pump is designed for ... high chemical resistance, quiet running and eliminates oil ... any oil to operate. Less mess, less fuss., ... 4-headed design with chemically resistant solid ETFE and ...
... several different two-stage, oil-sealed, rotary vane vacuum ... applications. Each pump comes complete with a ... and Oil Mist Filter (EMF-10). The GBORK ... ballast to keep the oil clean without ...
Medicine Products: